Kabir Nath, Compass Pathways CEO
Compass' single-dose psilocybin shows strong efficacy in PhII treatment-resistant depression trial
Treatment-resistant depression may have finally met its match (for some) as new Phase II results published in the New England Journal of Medicine yesterday show …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
